GLYAIR SMART
GLYAIR smart offers Breathing Space in COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that causes airflow blockages and breathing-related problems. Symptoms of COPD can include shortness of breath, coughing, and wheezing. COPD can be caused by smoking, but it can also be caused by other factors, such as exposure to secondhand smoke, air pollution, or certain chemicals.
There is no cure for COPD, but there are treatments that can help manage the symptoms and improve quality of life. One of these treatments is GLYAIR smart, a long-acting bronchodilator that provides 24-hour relief of COPD symptoms.
What is GLYAIR smart?
GLYAIR smart is a respule, which means that it is a pre-filled capsule that is used with a nebulizer. To use GLYAIR smart, simply attach the respule to your nebulizer and follow the instructions that come with your device. You will need to take GLYAIR smart twice a day, once in the morning and once in the evening.
GLYAIR smart contains a medication called glycopyrronium, which works by blocking the effects of a natural substance called acetylcholine. Acetylcholine is a chemical that causes the airways to narrow, which can make it difficult to breathe. By blocking the effects of acetylcholine, glycopyrronium helps to keep the airways open and makes it easier to breathe.
GLYAIR smart has been shown to be effective in improving COPD symptoms, such as shortness of breath, coughing, and wheezing. It has also been shown to reduce the risk of COPD exacerbations, which are episodes of worsening COPD symptoms. In addition, GLYAIR smart has been shown to improve lung function and quality of life in people with COPD.
How does GLYAIR smart work?
GLYAIR smart starts working within minutes of taking it and provides relief of COPD symptoms for up to 24 hours. It has been shown to be effective in improving COPD symptoms, such as shortness of breath, coughing, and wheezing. It has also been shown to reduce the risk of COPD exacerbations, which are episodes of worsening COPD symptoms. In addition, GLYAIR smart has been shown to improve lung function and quality of life in people with COPD.
What are the benefits of using GLYAIR smart?
GLYAIR smart offers a number of benefits for people with COPD, including:
Provides 24-hour relief of COPD symptoms
Starts working within minutes of taking it
Reduces the risk of COPD exacerbations
Improves lung function
Improves quality of life
How to use GLYAIR smart
To use GLYAIR smart, simply follow these steps:
Attach the respule to your nebulizer.
Follow the instructions that come with your nebulizer to turn it on.
Breathe in the mist from the nebulizer for 5-10 minutes.
Repeat steps 2-3 once more.
Dispose of the respule properly.
Who should not use GLYAIR smart?
GLYAIR smart should not be used by people who are allergic to glycopyrronium or any of the other ingredients in the medication. It should also not be used by people who have certain medical conditions, such as asthma, heart problems, or glaucoma.
What are the side effects of using GLYAIR smart?
GLYAIR smart can cause side effects, such as:
Dry mouth
Stuffy nose
Headache
Cough
Sore throat
Upset stomach
Dizziness
Blurred vision
Qualitative and Quantitative Composition
Qualitative Composition
Glycopyrronium (as glycopyrronium hydrobromide): 25 mcg
Excipients: Norflurane, ethanol, phosphoric acid, disodium edetate, and purified water.
Quantitative Composition
Glycopyrronium (as glycopyrronium hydrobromide): 25 mcg per actuation
Norflurane: 0.0177 mg per actuation
Ethanol: 1.4% v/v
Phosphoric acid: 0.26% w/v
Disodium edetate: 0.001% w/v
Purified water: up to 1 mL
It is important to note that the qualitative and quantitative composition of GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules may vary depending on the specific formulation. The information provided above is for general reference only.
It is also important to note that GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules contains a number of ingredients that are known to be allergens or irritants. If you have any concerns about using this product, you should consult with a doctor or pharmacist.
Dosage Form(S) and Strength(S)
The dosage form and strength of GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are as follows:
Dosage form: Inhalation solution respules
Strength: 25 mcg per actuation
GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is a clear, colorless solution that is packaged in a single-use respule. Each respule contains 1 mL of solution, which delivers 25 mcg of glycopyrronium.
GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is used to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by relaxing the muscles in the airways, making it easier to breathe.
GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is usually taken once a day, in the morning. It is important to use the respule as directed by your doctor. Do not use more or less of the respule than prescribed, and do not use it more often than once a day.
If you have any questions about GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules, please talk to your doctor or pharmacist.
Here are some additional details about the dosage form and strength of GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules:
The respules are clear, colorless, and odorless.
Each respule contains 1 mL of solution.
The solution delivers 25 mcg of glycopyrronium per actuation.
The respules are packaged in a single-use blister pack.
The respules should be stored at room temperature.
The respules should be discarded after they have been opened.
Clinical Particulars
Indication: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Dosage and administration: The recommended dosage of GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is one respule (delivering 25 mcg of glycopyrronium) once daily, in the morning. The respules should be used as directed by the patient's doctor.
Contraindications: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is contraindicated in patients with a known hypersensitivity to glycopyrronium or any of the excipients in the product.
Warnings and precautions: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules should be used with caution in patients with narrow-angle glaucoma, urinary retention, or prostatic hypertrophy. Patients should be advised to seek medical attention if they experience any of the following side effects: blurred vision, urinary retention, or constipation.
Adverse reactions: The most common adverse reactions reported with GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are dry mouth, headache, and upper respiratory tract infection.
Drug interactions: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules may interact with other medications, including anticholinergics, beta-blockers, and diuretics. Patients should tell their doctor about all the medications they are taking before starting GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules.
Overdosage: Overdosage with GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules may lead to symptoms such as dry mouth, blurred vision, urinary retention, and constipation. In case of overdosage, patients should seek medical attention immediately.
Pregnancy and lactation: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules should not be used during pregnancy or lactation unless the potential benefit outweighs the potential risk to the fetus or infant.
Storage: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules should be stored at room temperature (25°C to 30°C) and protected from light.
Pharmacological Properties
Mechanism of action: Glycopyrronium is a long-acting muscarinic receptor antagonist (LAMA). It works by blocking the action of acetylcholine, a neurotransmitter that causes the airways to narrow. By blocking the action of acetylcholine, glycopyrronium helps to relax the muscles in the airways, making it easier to breathe.
Pharmacokinetics: Glycopyrronium is well absorbed after inhalation. It reaches peak plasma concentrations within 15 minutes of administration. Glycopyrronium is metabolized in the liver and excreted in the urine. The half-life of glycopyrronium is approximately 35 hours.
Pharmacodynamics: Glycopyrronium has a long duration of action, providing bronchodilation for up to 24 hours. It is effective in improving lung function in patients with COPD. Glycopyrronium is also effective in reducing the number and severity of exacerbations of COPD.
Here are some additional details about the pharmacological properties of GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules:
Glycopyrronium is a quaternary ammonium compound, which means that it has a positive charge. This charge allows glycopyrronium to bind to the negatively charged muscarinic receptors in the airways.
Glycopyrronium is a high-affinity, long-acting muscarinic receptor antagonist. This means that it binds to the muscarinic receptors with a high degree of strength and it has a long duration of action.
Glycopyrronium is a selective muscarinic receptor antagonist. This means that it has a higher affinity for the muscarinic receptors in the airways than it does for the muscarinic receptors in other tissues, such as the heart and the bladder.
Glycopyrronium is a reversible muscarinic receptor antagonist. This means that it does not permanently block the action of acetylcholine. The effects of glycopyrronium wear off after the drug is cleared from the body.
Nonclinical Properties
Toxicology: Glycopyrronium was evaluated for its safety in a variety of animal studies. These studies showed that glycopyrronium is generally well tolerated and has a wide margin of safety. The most common adverse effects observed in animal studies were related to the muscarinic receptor-blocking activity of glycopyrronium, such as dry mouth, constipation, and urinary retention.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Glycopyrronium was not carcinogenic in long-term animal studies. It did not induce gene mutations or chromosomal damage in in vitro studies. Glycopyrronium did not impair fertility in male or female animals.
Developmental Toxicity: Glycopyrronium was not teratogenic in animal studies. However, it did cause some adverse effects in pregnant animals, such as decreased fetal weight and delayed ossification. These effects were likely due to the muscarinic receptor-blocking activity of glycopyrronium.
Pharmaceutical Particulars
Form: Inhalation solution respules
Dosage form: Clear, colorless solution
Strength: 25 mcg glycopyrronium per actuation
Excipients: Norflurane, ethanol, phosphoric acid, disodium edetate, and purified water
Route of administration: Inhalation
Storage: Store at room temperature (25°C to 30°C) and protected from light.
Stability: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is stable for 30 months from the date of manufacture.
Dispensing: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are dispensed in a single-use respule. Each respule contains 1 mL of solution.
Packaging: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are packaged in a carton containing 30 respules.
Patient Counselling Information
Indication: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Dosage and administration: The recommended dosage of GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is one respule (delivering 25 mcg of glycopyrronium) once daily, in the morning. The respules should be used as directed by the patient's doctor.
Contraindications: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules is contraindicated in patients with a known hypersensitivity to glycopyrronium or any of the excipients in the product.
Warnings and precautions: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules should be used with caution in patients with narrow-angle glaucoma, urinary retention, or prostatic hypertrophy. Patients should be advised to seek medical attention if they experience any of the following side effects: blurred vision, urinary retention, or constipation.
Adverse reactions: The most common adverse reactions reported with GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are dry mouth, headache, and upper respiratory tract infection.
Drug interactions: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules may interact with other medications, including anticholinergics, beta-blockers, and diuretics. Patients should tell their doctor about all the medications they are taking before starting GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules.
Overdosage: Overdosage with GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules may lead to symptoms such as dry mouth, blurred vision, urinary retention, and constipation. In case of overdosage, patients should seek medical attention immediately.
Pregnancy and lactation: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules should not be used during pregnancy or lactation unless the potential benefit outweighs the potential risk to the fetus or infant.
Storage: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules should be stored at room temperature (25°C to 30°C) and protected from light.
Dispensing: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are dispensed in a single-use respule. Each respule contains 1 mL of solution.
Packaging: GLYAIR smart glycopyrronium 25 mcg Inhalation solution respules are packaged in a carton containing 30 respules.
About INTRA LIFE PRIVATE LIMITED
INTRA LIFE PRIVATE LIMITED is a leading pharmaceutical company in India that is committed to providing high-quality, affordable medications to patients around the world. INTRA LIFE PRIVATE LIMITED has a strong focus on research and development, and is constantly working to bring new and innovative treatments to market. The company is also committed to providing education and support to patients and healthcare professionals.
GLYAIR smart is one of the latest products from INTRA LIFE PRIVATE LIMITED. It is a unique long-acting muscarinic antagonist that has been shown to be effective in improving COPD symptoms. GLYAIR smart is available in a respule, which makes it easy to use and convenient to take.